KoBioLabs, Inc (KOSDAQ:348150)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,950.00
+210.00 (3.66%)
At close: Apr 1, 2026
Market Cap115.54B +26.4%
Revenue (ttm)69.29B +1.4%
Net Income-6.33B
EPS-326.00
Shares Out19.42M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume410,847
Average Volume872,964
Open5,950.00
Previous Close5,740.00
Day's Range5,780.00 - 6,110.00
52-Week Range3,730.00 - 8,730.00
Beta0.61
RSI50.46
Earnings DateNov 14, 2025

About KoBioLabs

KoBioLabs, Inc. provides microbiome therapeutics for metabolic, immune, and brain diseases. The company was founded in 2014 and is based in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2014
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 348150
Full Company Profile

Financial Performance

In 2025, KoBioLabs's revenue was 69.29 billion, an increase of 1.36% compared to the previous year's 68.36 billion. Losses were -6.33 billion, 19.5% more than in 2024.

Financial Statements